NO751125L - - Google Patents
Info
- Publication number
- NO751125L NO751125L NO751125A NO751125A NO751125L NO 751125 L NO751125 L NO 751125L NO 751125 A NO751125 A NO 751125A NO 751125 A NO751125 A NO 751125A NO 751125 L NO751125 L NO 751125L
- Authority
- NO
- Norway
- Prior art keywords
- iii
- methyl
- phenylpropylamino
- propyl
- hydroxy
- Prior art date
Links
- PTGXAUBQBSGPKF-UHFFFAOYSA-N 4-[1-hydroxy-2-(4-phenylbutan-2-ylamino)propyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)CCC1=CC=CC=C1 PTGXAUBQBSGPKF-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- OWQUZNMMYNAXSL-UHFFFAOYSA-N diphenylpyraline Chemical compound C1CN(C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 OWQUZNMMYNAXSL-UHFFFAOYSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- -1 compound [4-(diphenylmethoxy)-1-methylpiperidinium]-4-[1-hydroxy-2-(1-methyl-3-phenylpropylamino)propyl]phenolate Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 11
- 210000004051 gastric juice Anatomy 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229940031826 phenolate Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000000181 anti-adherent effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229930182480 glucuronide Natural products 0.000 description 2
- 150000008134 glucuronides Chemical class 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229960003455 buphenine Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000879 diphenylpyraline Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2416253A DE2416253A1 (de) | 1974-04-03 | 1974-04-03 | Eckige klammer auf 4-(diphenylmethoxy) -1-methylpiperidinium eckige klammer zu -4eckige klammer auf 1-hydroxy-2-(1-methyl-3phenylpropylamino)propyl eckige klammer zu phenolat, verfahren zu seiner herstellung und seine verwendung in arzneimitteln |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO751125L true NO751125L (fr) | 1975-10-06 |
Family
ID=5912069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO751125A NO751125L (fr) | 1974-04-03 | 1975-04-02 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US3978220A (fr) |
| JP (1) | JPS5244367B2 (fr) |
| AT (1) | AT341524B (fr) |
| BE (1) | BE827469A (fr) |
| CA (1) | CA1027126A (fr) |
| CH (1) | CH593937A5 (fr) |
| DD (1) | DD118281A5 (fr) |
| DE (1) | DE2416253A1 (fr) |
| DK (1) | DK140775A (fr) |
| ES (1) | ES436231A1 (fr) |
| FI (1) | FI750973A (fr) |
| FR (1) | FR2266505B1 (fr) |
| GB (1) | GB1469208A (fr) |
| HU (1) | HU169800B (fr) |
| IL (1) | IL46990A (fr) |
| LU (1) | LU72201A1 (fr) |
| NL (1) | NL7503853A (fr) |
| NO (1) | NO751125L (fr) |
| SE (1) | SE7503777L (fr) |
| SU (1) | SU576926A3 (fr) |
| ZA (1) | ZA752069B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8480671B2 (en) | 2010-01-22 | 2013-07-09 | Covidien Lp | Compact jaw including split pivot pin |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3280196A (en) * | 1962-05-25 | 1966-10-18 | S B Penick & Company | Benzhydryl-dihaloalkane ethers |
-
1974
- 1974-04-03 DE DE2416253A patent/DE2416253A1/de not_active Withdrawn
-
1975
- 1975-03-25 CA CA223,078A patent/CA1027126A/fr not_active Expired
- 1975-04-01 US US05/564,189 patent/US3978220A/en not_active Expired - Lifetime
- 1975-04-01 IL IL46990A patent/IL46990A/xx unknown
- 1975-04-01 NL NL7503853A patent/NL7503853A/xx not_active Application Discontinuation
- 1975-04-01 JP JP50040205A patent/JPS5244367B2/ja not_active Expired
- 1975-04-02 HU HUTO999A patent/HU169800B/hu unknown
- 1975-04-02 DK DK140775A patent/DK140775A/da unknown
- 1975-04-02 AT AT250875A patent/AT341524B/de not_active IP Right Cessation
- 1975-04-02 BE BE155013A patent/BE827469A/fr unknown
- 1975-04-02 SE SE7503777A patent/SE7503777L/xx unknown
- 1975-04-02 ES ES436231A patent/ES436231A1/es not_active Expired
- 1975-04-02 ZA ZA00752069A patent/ZA752069B/xx unknown
- 1975-04-02 FI FI750973A patent/FI750973A/fi not_active Application Discontinuation
- 1975-04-02 FR FR7510242A patent/FR2266505B1/fr not_active Expired
- 1975-04-02 DD DD185173A patent/DD118281A5/xx unknown
- 1975-04-02 NO NO751125A patent/NO751125L/no unknown
- 1975-04-02 SU SU7502118671A patent/SU576926A3/ru active
- 1975-04-02 CH CH418475A patent/CH593937A5/xx not_active IP Right Cessation
- 1975-04-03 LU LU72201A patent/LU72201A1/xx unknown
- 1975-04-03 GB GB1364675A patent/GB1469208A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| SU576926A3 (ru) | 1977-10-15 |
| DE2416253A1 (de) | 1975-11-13 |
| CH593937A5 (fr) | 1977-12-30 |
| DK140775A (fr) | 1975-10-04 |
| FR2266505B1 (fr) | 1978-11-10 |
| BE827469A (fr) | 1975-10-02 |
| DD118281A5 (fr) | 1976-02-20 |
| SE7503777L (sv) | 1975-10-06 |
| IL46990A (en) | 1978-03-10 |
| AT341524B (de) | 1978-02-10 |
| ATA250875A (de) | 1977-06-15 |
| GB1469208A (en) | 1977-04-06 |
| AU7973275A (en) | 1976-10-07 |
| ZA752069B (en) | 1976-07-28 |
| LU72201A1 (fr) | 1976-03-02 |
| JPS5244367B2 (fr) | 1977-11-08 |
| CA1027126A (fr) | 1978-02-28 |
| FI750973A (fr) | 1975-10-04 |
| IL46990A0 (en) | 1975-07-28 |
| ES436231A1 (es) | 1977-01-01 |
| JPS50154409A (fr) | 1975-12-12 |
| NL7503853A (nl) | 1975-10-07 |
| FR2266505A1 (fr) | 1975-10-31 |
| HU169800B (fr) | 1977-02-28 |
| US3978220A (en) | 1976-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR900000869B1 (ko) | 소염 및 진통작용을 갖는 화합물의 수용성염류의 제조방법 | |
| ES2954451T3 (es) | Composiciones y usos de derivados de amidina | |
| JPH07501330A (ja) | 新規な置換されたサリチル酸 | |
| DK162840B (da) | Zink(ii)-komplekser af substituerede 3-hydroxypyroner eller 3-hydroxypyridoner, anvendelse af disse samt farmaceutiske praeparater indeholdende disse | |
| AU652951B2 (en) | Codeine salt of a substituted carboxylic acid, processes for the preparation thereof, its use and pharmaceutical compositions | |
| FI89598B (fi) | Foerfarande foer framstaellning av vattenfritt, kristallint natriumsalt av 5-klor-3-(2-tenoyl)-2-oxindol-1-karboxamid som laempar sig foer anvaendning som analgetiskt eller antiinflammatoriskt medel | |
| BR112020006669A2 (pt) | formas cristalinas de 1,2,4-oxadiazol 3-substituído | |
| IE47072B1 (en) | N-acetyl-para-aminohenyl-n'-acetyl-aminothioalkanoic acid ester derivatives | |
| US4152448A (en) | Method and composition for the treatment of a condition of the gastro intestinal tract | |
| JPH0148247B2 (fr) | ||
| WO2005123651A1 (fr) | L-2-(a-hydroxypentyle)benzoates, leur elaboration et leur utilisation | |
| JPH0222271A (ja) | 共役γ−オキシブテノライド化合物およびこれを有効成分とする抗潰瘍剤 | |
| CA2949663A1 (fr) | Derives de dipicolylamine et leurs utilisations pharmaceutiques | |
| US4103009A (en) | Benzoguanamine derivatives | |
| NO751125L (fr) | ||
| PT96447B (pt) | Processo para a preparacao de um hemi-hidrato de um derivado de tetra-hidroimidazo-piridina | |
| GB2098215A (en) | Thiazolidine derivatives and their preparation and pharmaceutical formulation | |
| JPS5867618A (ja) | １―アザキサントンからなる医薬 | |
| US3953601A (en) | Dibenzothiophene derivatives as serum lipid lowering agents | |
| WO2005021481A1 (fr) | Sel n,n'-dibenzyl ethylenediamine d'acide benzoique 2-(alpha-hydroxypentyl) et procede de preparation et utilisation correspondante | |
| JPS60501561A (ja) | アゾ−ビス−サリチル酸およびその塩、該酸および該塩の薬学的処方および使用、並びに該酸の製造 | |
| JPS5951954B2 (ja) | インド−ル酢酸イソベンゾフラニルエステル、その製造方法及びそれを含有する鎮痛及び抗炎症剤 | |
| US4371535A (en) | Method of and composition for delivering 5-fluorouracil to tumors | |
| US5489609A (en) | 2-aminoethanesulfonic acid zinc complex compound | |
| JPS6253954A (ja) | フエニルアラニン誘導体およびその用途 |